Emergências e Terapia Intensiva
Recomendações baseadas em consenso para o tratamento da via aérea complicada, parte 1. Tratamento da via aérea complicada em um paciente inconsciente.
21 Jun, 2021 | 10:49hEstudo randomizado | Uso rotineiro, profilático e pós-cirúrgico da pressão positiva contínua na via aérea (continuous positive airway pressure – CPAP) não previne pneumonia, reintubação e morte após cirurgia abdominal maior.
21 Jun, 2021 | 10:49hPostoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial – The Lancet Respiratory Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter (fio – clique para saber mais)
Published today in @LancetRespirMed is the final report of @prismtrial, an international multi-centre phase-3 randomised trial of routine postoperative CPAP to prevent pneumonia, re-intubation & death after major abdominal surgery https://t.co/e09pSTi2sa @rupert_pearse @QMULWHRI
— Tom Abbott (@_tomabbott) June 19, 2021
Recomendações da ECMM/ISHAM para o manejo clínico da mucormicose associada à COVID-19 em países de baixa e média rendas.
18 Jun, 2021 | 10:34hEstudo de coorte | Desfechos relacionados a deglutição e voz em pacientes hospitalizados com COVID-19.
18 Jun, 2021 | 10:33hEstudo relacionado: Characterization of dysphagia and laryngeal findings in COVID-19 patients treated in the ICU—An observational clinical study – PLOS One
Comentário sobre estudo | História da hipotermia na parada cardíaca, 2002-2021 (RIP).
18 Jun, 2021 | 10:29hA history of hypothermia for cardiac arrest, 2002-2021 (RIP) – PulmCrit
Estudo original: RCT: In patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not improve outcomes.
Comentário no Twitter
A history of hypothermia for cardiac arrest, 2002-2021 (RIP)🪦
🥶2002 studies supporting hypothermia were weak
🥶robust studies refute benefit (TTM1 & TTM2)
🥶growing evidence of iatrogenic harm
🥶post-arrest hypothermia should be restricted to within RCTshttps://t.co/GZbpgHXWoD pic.twitter.com/ILUAiqqLQl— 𝙟𝙤𝙨𝙝 𝙛𝙖𝙧𝙠𝙖𝙨 💊 (@PulmCrit) June 17, 2021
Estudo randomizado | Tofacitinibe reduziu o risco de morte ou insuficiência respiratória em pacientes hospitalizados com pneumonia por Covid-19.
17 Jun, 2021 | 11:06hTofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine
Comunicado de imprensa: Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia
Comentário no Twitter:
Patients who were hospitalized with #COVID19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group. #IDTwitter
— NEJM (@NEJM) June 16, 2021
[Preprint] Estudo RECOVERY descobre que a combinação de anticorpo monoclonal Regeneron reduz as mortes de pacientes hospitalizados com COVID que não desenvolveram sua própria resposta imunológica.
17 Jun, 2021 | 11:04hComunicado de imprensa: RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response
Estudo original (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv
Comentários: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science E Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP E Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT E Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre
Comentário no Twitter
RECOVERY Pre-print:
In patients hospitalised with COVID-19 but no natural antibody response, monoclonal antibody infusion:
– reduced mortality
– increased speed of discharge
– reduced progression to invasive mechanical ventilation or deathhttps://t.co/rpDk4eUhmm pic.twitter.com/wXegKcDZg8— Martin Landray (@MartinLandray) June 16, 2021
Agora, o CDC chama a variante Delta do coronavírus de “variante de preocupação”.
17 Jun, 2021 | 11:02hCDC now calls coronavirus Delta variant a ‘variant of concern’ – CNN
Diretriz: SARS-CoV-2 Variant Classifications and Definitions – Centers for Disease Control and Prevention
Comentário no Twitter
BREAKING—CDC now officially declares #DeltaVariant a “variant of concern”—because much more transmissible (50% faster than #B117, 2x than original strain), more severe (2.5x hospitalization risk than B117, 4x original) & 1 dose vaccine evasive.🧵 #COVID19https://t.co/jZCgfzFLla pic.twitter.com/SszvXuysze
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
Série de casos | 7 casos de miocardite após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 11:00hMyocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation
Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Série de casos | Achados clínicos e de ressonância magnética em 4 casos de miocardite após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 10:58hComentário: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.